Table 1.
Patient | Treatment1 | Stage at Diagnosis2 | Diagnostic biopsy grade & histology | Diagnostic biopsy cellularity3 | Surgical biopsy grade & histology | Surgical biopsy cellularity3 | Pathological stage4 |
---|---|---|---|---|---|---|---|
CRT1 | CRT | T2N1 M0 | moderately differentiated adenocarcinoma | 60% | poorly differentiated adenocarcinoma | 60% | T3N2 |
CRT2 | CRT | T3N1 M0 | moderately differentiated adenocarcinoma | 60% | moderately differentiated adenocarcinoma | 60% | T3N1 |
CRT3 | CRT | T3N0 M0 | moderately differentiated adenocarcinoma | 60% | moderately differentiated adenocarcinoma | 50% | T3N0 |
CRT4 | CRT | T4N1 M0 | moderately differentiated adenocarcinoma | 50% | moderately differentiated adenocarcinoma | 50% | T2N0 |
RT1 | RT | T2N0 M0 | moderately differentiated adenocarcinoma | 60% | moderately differentiated adenocarcinoma | 60% | T3N0 |
RT2 | RT | T2N1 M0 | moderately differentiated adenocarcinoma | 60% | moderately differentiated adenocarcinoma | 60% | T2N1 |
RT3 | RT | T2N0 M0 | moderately differentiated adenocarcinoma | 50% | moderately differentiated adenocarcinoma | 60% | T3N2 |
RT4 | RT | T2N0 M0 | moderately differentiated adenocarcinoma | 60% | moderately differentiated adenocarcinoma | 60% | T3N0 |
CON1 | None | T3N1 M0 | moderately differentiated adenocarcinoma | 75% | moderately differentiated adenocarcinoma | 70% | T3N1 |
CON2 | None | T2N1 M0 | moderately differentiated adenocarcinoma | 50% | moderately differentiated adenocarcinoma | 50% | T3N1 |
1 CRT = neoadjuvant concurrent chemoradiotherapy; RT = Short course pre-operative radiotherapy. 2 MRI and clinical stage. 3 % Tumour versus normal cells in biopsy profiled. 4 Pathological stage post-preoperative therapy